药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(20212318452732.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文CINVANTI 处方资料(仅供参考)
【英文名称】CINVANTI
【适用证】
CINVANTI是一种P /神经激肽-1(NK 1)受体拮抗剂,在成人中与其他止吐剂联合使用,用于预防:
- 与高致吐性癌症化疗(HEC)(包括高剂量顺铂)的初始和重复疗程相关的急性和迟发性恶心和呕吐。
--与中度致吐性癌症化疗(MEC)的初始和重复疗程相关的恶心和呕吐。
使用限制:
尚未研究CINVANTI治疗已确诊的恶心和呕吐。
【用法用量】
推荐剂量:
---静脉注射CINVANTI注射2分钟或注射30分钟以上; 在化疗前约30分钟完成注射或输注。
--- HEC(单剂量方案):成人的推荐剂量在第1天为130 mg。
--- MEC(3天方案):在第1天给予成人的推荐剂量为100mg。在第2天和第3天口服给予阿瑞匹坦胶囊(80mg)。
--- CINVANTI是包含皮质类固醇和5-HT拮抗剂的方案的一部分。
的制备:将
有关说明,请参阅完整的处方信息。
【禁忌】
- 已知对该药物的任何成分过敏。
- 与pimozide同时使用。
【使用注意】
CYP3A4相互作用:Aprepitant是一种底物,弱至中度(剂量依赖性)抑制剂和CYP3A4诱导剂; 有关CINVANTI和伴随药物的禁忌症,不良反应风险和剂量调整的建议,请参阅完整处方信息。
超敏反应(包括过敏反应):可能在给药期间或之后不久发生。 如果出现症状,请停止使用CINVANTI并且不要重新开始。
华法林(CYP2C9底物):凝血酶原时间INR降低的风险; 在CINVANTI开始后2周内监测INR,特别是7至10天。
荷尔蒙避孕药:避孕药的使用效果可在服用阿瑞吡坦后28天内减少。 使用有效的替代或备用非激素避孕方法。
【INDICATIONS AND USAGE】
CINVANTI is a substance P/neurokinin-1 (NK 1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of:
---acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
---nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Limitations of Use:
CINVANTI has not been studied for treatment of established nausea and vomiting.
【CONTRAINDICATIONS】
--Known hypersensitivity to any component of this drug
--Concurrent use with pimozide.
【WARNINGS AND PRECAUTIONS】
CYP3A4 Interactions: Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor and an inducer of CYP3A4; see Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of CINVANTI and concomitant drugs.
Hypersensitivity Reactions (including anaphylaxis): May occur during or soon after administration. If symptoms occur, discontinue CINVANTI and do not reinitiate it.
Warfarin (a CYP2C9 substrate): Risk of decreased INR of prothrombin time; monitor INR in 2–week period, particularly at 7 to 10 days, following initiation of CINVANTI.
Hormonal Contraceptives: Efficacy of contraceptives may be reduced during and for 28 days following administration of aprepitant. Use effective alternative or back-up methods of non-hormonal contraception.
【DOSAGE AND ADMINISTRATION】
Recommended Dosage :
---Administer CINVANTI intravenously as an injection over 2 minutes or an infusion over 30 minutes; complete the injection or infusion approximately 30 minutes prior to chemotherapy.
---HEC (Single Dose Regimen): The recommended dosage in adults is 130 mg on Day 1.
---MEC (3-Day Regimen): The recommended dosage in adults is 100 mg administered on Day 1. Aprepitant capsules (80 mg) are given orally on Days 2 and 3.
---CINVANTI is part of a regimen that includes a corticosteroid and a 5-HT antagonist.
Preparation:
See the full prescribing information for instructions.
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(20212318452732.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |